5-bromo-1-phenylpent-3-en-1-yne | 287471-31-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-bromo-1-phenylpent-3-en-1-yne
• 英文别名: (E)-(5-bromopent-3-en-1-yn-1-yl)benzene；(E)-(5-bromo-pent-3-en-1-ynyl)-benzene；[(E)-5-bromopent-3-en-1-ynyl]benzene
• CAS: 287471-31-2
• 化学式: C₁₁H₉Br
• 分子量: 221.096
• InChiKey: KFKLYSZHDZWMBN-QHHAFSJGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  5-bromo-1-phenylpent-3-en-1-yne 在 sodium hydride 、 三乙胺 、 甲烷磺酰基叠氮化物 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 反应 5.0h， 生成 (E)-3-Diazo-10-phenyl-dec-7-en-9-yne-2,4-dione
  参考文献：
  名称：

  Asymmetric intramolecular cyclopropanation of diazo compounds with metallosalen complexes as catalyst: structural tuning of salen ligand

  摘要：

  Intramolecular cyclopropanation of alkenyl alpha-diazoacetates and alkenyl diazomethyl ketones was examined by using optically active (ON+)Ru(11)(salen) and Co(II)(salen) complexes as catalysts. For the cyclization of 2-alkenyl alpha-diazoacetates, Co(II)(salen) complexes 9 and 10 were found to be superior catalysts to the corresponding (ON+)Ru(11)(salen) complexes 4 and 5. On the other hand, (ON+)Ru(II)(salen) complex 2 was found to be the catalyst of choice for the cyclization of 3-alkenyl diazomethyl ketones, and complex 4 was found to be a good catalyst for the cyclization of (E)-4-alkenyl diazomethyl ketones. The present study demonstrates that metallosalen complexes, especially optically active (ON+)Ru(II)(salen) and Co(11)(salen) complexes, can serve as efficient catalysts for the cyclization of alkenyl diazocarbonyl compounds, if a suitable salen ligand is used as the chiral auxiliary. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(03)00167-8
• 作为产物：
  描述：

  (E)-5-phenyl-penta-2-ene-4-yne-1-ol 在 phosphorus tribromide 作用下， 以 甲苯 为溶剂， 生成 5-bromo-1-phenylpent-3-en-1-yne
  参考文献：
  名称：

  New compounds, their preparation and use

  摘要：

  本发明涉及式(I)的化合物。 这些化合物在治疗和/或预防由核受体介导的疾病中具有用途，特别是过氧化物酶体增殖激活受体（PPAR）。

  公开号：

  US20010041709A1

文献信息

• New compounds, their preparation and use
  申请人：——

  公开号：US20010041709A1

  公开（公告）日：2001-11-15

  The present invention relates to compounds of formula (I) 1 The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

  本发明涉及式(I)的化合物。 这些化合物在治疗和/或预防由核受体介导的疾病中具有用途，特别是过氧化物酶体增殖激活受体（PPAR）。
• A stereoselective synthesis of (E)-1-halo-6,6-dimethyl-2-hepten-4-yne: a key intermediate for terbinafine
  作者：Shan-Yen Chou、Chin-Lu Tseng、Shyh-Fong Chen

  DOI：10.1016/s0040-4039(00)00511-6

  日期：2000.5

  A study of the stereoselective halogenation of 6,6-dimethyl-1-hepten-4-yn-3-ol (1) using a series of halogenating agents is described. Of the many agents investigated, boron trichloride is the most successful reagent for stereoselective halogenation (E:Z=9:1max). The resulting (E)-1-halo-6,6-dimethyl-2-hepten-4-yne (2), a key intermediate for terbinafine, an antifungal agent, is obtained in good yield

  描述了使用一系列卤化剂对6,6-二甲基-1-庚烯-4-yn-3-ol（1）进行立体选择性卤化的研究。在研究的许多试剂中，三氯化硼是最成功的立体选择性卤化试剂（E：Z = 9：1 max）。以良好的收率和立体选择性获得了所得的（E）-1-卤代-6,6-二甲基-2-庚基-4-炔（2），这是特比萘芬（一种抗真菌剂）的关键中间体。同样研究了两种结构相关的炔烃，并显示了相似的通用性。
• A highly practical approach to chiral homoallylic–homopropargylic amines via aza-Barbier reaction
  作者：Bin-Hua Yuan、Zhi-Cheng Zhang、Wen-Jie Liu、Xing-Wen Sun

  DOI：10.1016/j.tetlet.2016.03.103

  日期：2016.5

  The first access to chiral homoallylic–homopropargylic amine bearing two contiguous stereocenters has been well accomplished via zinc-promoted aza-Barbier reaction. N-tert-Butanesulfinyl ketimines are well-tolerated substrates, providing the tertiary amines in high yields and with excellent diastereoselectivities. 3,4-Dihydro-2H-pyrroles could be prepared in high efficiency by cyclization of the corresponding

  通过锌促进的氮杂-巴比尔反应已经很好地实现了首次获得具有两个连续立体中心的手性均烯丙基-同炔丙基胺。ñ -叔-Butanesulfinyl酮亚胺是耐受性良好的基板，提供以高收率和优异的非对映选择性的叔胺。通过将相应的胺环化，可以高效地制备3，4-二氢-2 H-吡咯。
• Combination therapy using a dual PPAR-a/PPAR-y activator and a GLP-1 derivative for the treatment of metabolic syndrome and related diseases and disorders
  申请人：——

  公开号：US20030199451A1

  公开（公告）日：2003-10-23

  The present invention relates to a pharmaceutical composition comprising a dual Peroxisome Proliferator-Activated Receptor-alpha/Peroxisome Proliferator-Activated Receptor-gama activator (PPAR-&agr;/PPAR-&ggr;) and a Glucagon Like Peptide-1 (GLP-1) derivative for treating, preventing and reducing the risk of developing Type 2 diabetes, insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.

  本发明涉及一种药物组成物，包括一个双过氧化物酶体增殖物激活受体-α/过氧化物酶体增殖物激活受体-γ激活剂（PPAR-α/PPAR-γ）和一种胰高血糖素样肽-1（GLP-1）衍生物，用于治疗、预防和降低发展2型糖尿病、胰岛素抵抗、血脂异常、肥胖症、高血压和其他相关疾病和障碍的风险。
• Alkynyl-substituted propionic acid derivatives, their preparation and use
  申请人：Novo Nordisk A/S

  公开号：US06569901B2

  公开（公告）日：2003-05-27

  The present invention relates to compounds of formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

  本发明涉及公式(I)的化合物。这些化合物可用于治疗和/或预防由核受体介导的疾病，尤其是过氧化物酶体增殖物激活受体(PPAR)介导的疾病。